Please ensure Javascript is enabled for purposes of website accessibility

Why Aerie Pharmaceuticals Is Rocketing Higher Today

By Todd Campbell - Sep 17, 2015 at 1:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Positive efficacy for Rhopressa suggests a filing for approval in 2016 and potential commercialization in 2017.

Source: Aerie Pharmaceuticals

What: After reporting positive phase 3 results and outlining the timing for an FDA filing for approval of its glaucoma drug, shares in Aerie Pharmaceuticals (AERI -7.59%) shot higher by 74% earlier today on tremendous volume.

So what: Aerie Pharmaceuticals is a clinical-stage company that is developing Rhopressa, a medicine delivered via eye drops that can reduce intraocular pressure associated with glaucoma or ocular hypertension.

In its phase 3 Rocket 2 trial, once-daily Rhopressa met its primary endpoint of demonstrating non-inferiority to twice-daily timolol, a generic therapy that is widely used in this patient population.

Following Rhopressa's phase 3 success, the company awaits one year safety results from Rocket 2, which should be available either by the end of this year or by early next year. If that safety data is solid, then a filing for Rhopressa's approval with the FDA could occur by the middle of next year.

Now what: The positive Rocket 2 results help restore confidence in Aerie Pharmaceuticals that was lost following the release of disappointing phase 3 results from its Rocket 1 trial earlier this year. In Rocket 1, Rhopressa failed to meet its primary endpoint of non-inferiority to timolol.

After the company analyzed its Rocket 1 results, it adjusted the criteria for patients to be included in Rocket 2 to those with intraocular pressure of between 20 mmHg and 25 mmHg -- a patient population that comprises roughly 80% of all glaucoma patients and for which Rhopressa successfully demonstrated non-inferiority to timolol in Rocket 1.

Based on Rocket 2's results, revising the endpoint was the right move by Aerie Pharmaceuticals. If positive safety data allows for a mid year filing for approval in 2016, then Aerie Pharmaceuticals could begin generating sales in 2017.

That's a pretty favorable timeline, but investors should bear in mind that although Aerie Pharmaceuticals has previously indicated that cash on hand should fund its operations through 2017, it's not clear if that belief reflects spending that would need to be made -- absent a licensing deal -- to prepare it to commercialize Rhopressa. If it doesn't, then a dilutive stock offering could be coming -- especially in light of the dramatic increase in the company's shares today. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aerie Pharmaceuticals, Inc. Stock Quote
Aerie Pharmaceuticals, Inc.
AERI
$5.48 (-7.59%) $0.45

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
322%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.